Non-Invasive Imaging Compared with Intra-Arterial Angiography in the Diagnosis of Symptomatic Carotid Stenosis: A Meta-Analysis
Lancet 367:1503-1512, Wardlaw,J.M.,et al, 2006
Thrombosis of the Cerebral VEins and Sinuses
NEJM 352:1791-1798, Stam,J., 2005
Imaging-Based Decision Making in Thrombolytic Therapy for Ischemic Stroke
Stroke 34:575-583, Schellinger,P.D.,et al, 2003
Thunderclap Headache
JNNP 72:6-11, Dodick,D.W., 2002
Intraarterial Thrombolysis: Ready for Prime Time?
AJNR 22:55-58, Executive Committee of the ASITN, 2001
Prethrombolysis Brain Imaging:Trends and Controversies
AJNR 18:1830-1834, Castillo,M., 1997
Patent Foramen Ovale Management for Secondary Stroke Prevention:State-of-the-Art Appraisal of Current Evidence
Stroke 55:236-247, Sposato,L.A.,et al, 2024
Endovascular Therapy or Medical Management Alone for Isolated Posterior Cerebral Artery Occlusion: A Multicenter Study
Stroke 54:928-937, Sabben,C.,et al, 2023
Thrombectomy versus Medical Management in Mild Strokes due to Large Vessel Occlusion: Exploratory Analysis from the EXTEND-IA Trials and a Pooled International Cohort
Ann Neurol 92:364-378, Sarraj, A.,et al, 2022
Administering Thrombolysis for Acute Ischemic Stroke in Patients Taking Direct Oral Anticoagulants
JAMA Neurol 78:515-518, Seiffge, D.J.,et al, 2021
Medical Management vs Mechanical Thrombectomy for Mild Strokes
JAMA Neurol 77:16-24, Goyal, N.,et al, 2020
Thrombolytic Therapy for Acute Central Retinal Artery Occlusion
Stroke 51:687-695, Mac Grory, B.,et al, 2020
Intravenous Thrombolysis for Suspected Ischemic Stroke with Seizure at Onset
Ann Neurol 86:770-779, Polymeris, A.A.,et al, 2019
Primary Thrombectomy in tPA (Tissue-Type Plasminogen Activator) Eligible Stroke Patients with Proximal Intracranial Occlusions
Stroke 49:265-269, Fischer, U.,et al, 2018
Association of Spinal Manipulative Therapy with Clinical Benefit and Harm for Acute Low Back Pain
JAMA 317:1451-1460,1418, Paige, N.M.,et al, 2017
Direct Mechanical Thrombectomy Versus Combined Intravenous and Mechanical Thrombectomy in Large-Artery Anterior Circulation Stroke
Stroke 48:2912-2918, Fischer, U.,et al, 2017
Treatment and Outcome of Hemorrhagic Transformation after Intravenous Alteplase in Acute Ischemic Stroke
Stroke 48:e343-e361, Yaghi, S.,et al, 2017
Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic STroke
Stroke 47:581-641, Demaerschalk, B.M.,et al, 2016
Infective Endocarditis
Lancet 387:882-893, Cahill, T.J. & Prendergast, B.D., 2016
Repeated Intravenous Thrombolysis for Early Recurrent Stroke
Stroke 47:2133-2135, Kahles, T.,et al, 2016
Drip and Ship Versus Direct to Comprehensive Stroke Center
Stroke 48:233-238, Holodinsky, J.K.,et al, 2016
Microbleed Status and 3-Month Outcome After Intravenous Thrombolysis in 717 Patients with Acute Ischemic Stroke
Stroke 46:2458-2463,2403, Turc, G.,et al, 2015
Treatment Concepts for Wake-Up Stroke and Stroke with Unknown Time of Symptom Onset
Stroke 46:2707-2713, Thomalla, G. & Gerloff, C., 2015
Intravenous Fibrinolytic Therapy in Central Retinal Artery Occlusion
JAMA Neurol 72:1148-1154, Schrag, M.,et al, 2015
4.5-Hour Time Window for Intravenous Thrombolysis with Recombinant Tissue-Type Plasminogen Activator is Established Firmly
Stroke 45:912-913,916, Schellinger, P.D. & Kohrmann, M., 2014
The 4.5-HourTime Window for Intravenous Thrombolysis with Intravenous Tissue-Type Plasminogen Activator is Not Firmly Established
Stroke 45:915-915,916, Wechsler, L.R., 2014
Reperfusion Therapies for Wake-Up Stroke
Stroke 45:1869-1875, Buck, D.,et al, 2014
Safety of Thrombolysis in Patients with Acute Ischemic Stroke and Cerebral Cavernous Malformations
Stroke 45:1846-1848, Erdur, H.,et al, 2014
Endovascular Treatment for Acute Ischemic Stroke-Still Unproven
NEJM 368:952-955, Chimowitz,M., 2013
A Trial of Imaging Selection and Endovascular Treatment for Ischemic Stroke
NEJM 368:914-923,952, Kidwell, C.S.,et al, 2013
Endovascular Therapy after Intravenous t-PA versus t-PA Alone for Stroke
NEJM 368:893-903,952, Broderick, J.P.,et al, 2013
Endovascular Treatment for Acute Ischemic Stroke
NEJM 368:914-923,952, Ciccone, A.,et al, 2013
Treatment of Patients with Suspected Ischemic Stroke of Undetermined Onset and Negative Head Computed Tomography Scan
Stroke 44:1494-1495, Adams, H., 2013
A Plain Computed Tomography Scan is Sufficient to Consider Thrombolysis in Patients with Unknown Time of Onset
Stroke 44:1492-1493, Alexandrov, A., 2013
Carotid Stenosis
NEJM 369:1143-1150, Grotta, J., 2013
Thrombolysis for Ischemic Stroke Associated with Infective Endocarditis
Stroke 44:2917-2919, Asaithambi, G.,et al, 2013
Thrombolysis for Acute Ischemic Stroke in Patients with Cancer
Stroke 44:3573-3576, Murthy, S.B.,et al, 2013
The Types of Neurological Deficits Might Not Justify Withholding Treatment in Patients with Low Total National Institutes of Health Stroke Scale Scores
Stroke 43:782-786,625, Leira,E.C.,et al, 2012
Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
Elderly Patients are at Higher Risk for Poor Outcomes after Intra-Arterial Therapy
Stroke 43:2356-2361, Chandra, R.V.,et al, 2012
Percutaneous Vascular Interventions for Acute Ischemic Stroke
Stroke 42:e31-e32, ORourke,K.,et al, 2011
Bridging Intravenous-Inta-Arterial Rescue Strategy Increases Recanalization and the Likelihood of a Good Outcome in Nonresponder Intravenous Tissue Plasminogen Activator-Treated Patients: A Case-Control Study
Stroke 42:993-997, 880, Rubiera,M.,et al, 2011
Are all IV thrombolysis exclusion criteria necessary? Being SMART about evidence-based medicine
Neurol 76:1780-1781, Tong, D., 2011
Efficacy of Intravenous Tissue-Type Plasminogen Activator in Central Retinal Artery Occlusion Report From a Randomized, Controlled Trial
Stroke 42:2229-2234, Chen, C.S.,et al, 2011
Advanced Brain Imaging Studies Should Be Performed in Patients With Suspected Stroke Presenting Within 4.5 Hours of Symptom Onset
Stroke 42-2666-2667,2670, Parsons, M.W., 2011
Advanced Brain Imaging Studies Should Not Be Performed in Patients With Suspected Stroke Presenting Within 4.5 Hours of Symptom Onset
Stroke 42:2668-2669,2670, Lyden, P.D., 2011
Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
No-Go to Tissue Plasminogen Activator for Transient Ischemic Attack
Stroke 41:3005-3006, 3007, Liebeskind,D.S., 2010
Pro: Intravenous Tissue Plasminogen Activator in Stroke Patients With Rapid, Complete Recovery During Evaluation (Transient Ischemic Attack) and Evidence of Middle Cerebral Artery Occlusion
Stroke 41:3003-3004, 3007, K�hrmann,M. &Schellinger,P.D., 2010